Widdifield Cory M, Nilsson Lill Sten O, Broo Anders, Lindkvist Maria, Pettersen Anna, Svensk Ankarberg Anna, Aldred Peter, Schantz Staffan, Emsley Lyndon
Institut des Sciences Analytiques (CNRS/ENS de Lyon/UCB Lyon 1), Centre de RMN à Très Hauts Champs, Université de Lyon, 69100 Villeurbanne, France.
Phys Chem Chem Phys. 2017 Jun 28;19(25):16650-16661. doi: 10.1039/c7cp02349a.
The crystal structure of the Form A polymorph of N-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-pyrazin-1-yl]benzamide (i.e., AZD7624), determined using single-crystal X-ray diffraction (scXRD) at 100 K, contains two molecules in the asymmetric unit (Z' = 2) and has regions of local static disorder. This substance has been in phase IIa drug development trials for the treatment of chronic obstructive pulmonary disease, a disease which affects over 300 million people and contributes to nearly 3 million deaths annually. While attempting to verify the crystal structure using nuclear magnetic resonance crystallography (NMRX), we measured C solid-state NMR (SSNMR) spectra at 295 K that appeared consistent with Z' = 1 rather than Z' = 2. To understand this surprising observation, we used multinuclear SSNMR (H, C, N), gauge-including projector augmented-wave density functional theory (GIPAW DFT) calculations, crystal structure prediction (CSP), and powder XRD (pXRD) to determine the room temperature crystal structure. Due to the large size of AZD7624 (ca. 500 amu, 54 distinct C environments for Z' = 2), static disorder at 100 K, and (as we show) dynamic disorder at ambient temperatures, NMR spectral assignment was a challenge. We introduce a method to enhance confidence in NMR assignments by comparing experimental C isotropic chemical shifts against site-specific DFT-calculated shift distributions established using CSP-generated crystal structures. The assignment and room temperature NMRX structure determination process also included measurements of C shift tensors and the observation of residual dipolar coupling between C and N. CSP generated ca. 90 reasonable candidate structures (Z' = 1 and Z' = 2), which when coupled with GIPAW DFT results, room temperature pXRD, and the assigned SSNMR data, establish Z' = 2 at room temperature. We find that the polymorphic Form A of AZD7624 is maintained at room temperature, although dynamic disorder is present on the NMR timescale. Of the CSP-generated structures, 2 are found to be fully consistent with the SSNMR and pXRD data; within this pair, they are found to be structurally very similar (RMSD = 0.30 Å). We establish that the CSP structure in best agreement with the NMR data possesses the highest degree of structural similarity with the scXRD-determined structure (RMSD = 0.17 Å), and has the lowest DFT-calculated energy amongst all CSP-generated structures with Z' = 2.
N-环丙基-3-氟-4-甲基-5-[3-[[1-[2-[2-(甲氨基)乙氧基]苯基]环丙基]氨基]-2-氧代-吡嗪-1-基]苯甲酰胺(即AZD7624)A晶型的晶体结构,通过在100 K下使用单晶X射线衍射(scXRD)测定,其不对称单元中包含两个分子(Z' = 2),并且存在局部静态无序区域。该物质已进入治疗慢性阻塞性肺疾病的IIa期药物开发试验,这种疾病影响超过3亿人,每年导致近300万人死亡。在尝试使用核磁共振晶体学(NMRX)验证晶体结构时,我们在295 K下测量了碳固体核磁共振(SSNMR)光谱,其结果似乎与Z' = 1而非Z' = 2一致。为了解释这一惊人发现,我们使用多核SSNMR(氢、碳、氮)、包含规范的投影增强波密度泛函理论(GIPAW DFT)计算、晶体结构预测(CSP)和粉末X射线衍射(pXRD)来确定室温下的晶体结构。由于AZD7624尺寸较大(约500原子质量单位,Z' = 2时有54个不同的碳环境),在100 K时存在静态无序,并且(如我们所示)在环境温度下存在动态无序,因此核磁共振光谱归属是一项挑战。我们引入了一种方法,通过将实验测得的碳各向同性化学位移与使用CSP生成的晶体结构建立的位点特异性DFT计算的位移分布进行比较,来提高对核磁共振归属的置信度。归属和室温NMRX结构确定过程还包括测量碳位移张量以及观察碳和氮之间的残余偶极耦合。CSP生成了约90个合理的候选结构(Z' = 1和Z' = 2),这些结构与GIPAW DFT结果、室温pXRD以及已归属的SSNMR数据相结合,确定室温下Z' = 2。我们发现AZD7624的A晶型在室温下得以保持,尽管在核磁共振时间尺度上存在动态无序。在CSP生成的结构中,发现有2个与SSNMR和pXRD数据完全一致;在这一对结构中,它们在结构上非常相似(均方根偏差 = 0.30 Å)。我们确定与核磁共振数据最吻合的CSP结构与scXRD确定的结构具有最高程度的结构相似性(均方根偏差 = 0.17 Å),并且在所有Z' = 2的CSP生成结构中具有最低的DFT计算能量。